Revive Therapeutics Ltd.

DB:31R Stock Report

Market Cap: €2.8m

Revive Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Michael Frank

Chief executive officer

CA$360.0k

Total compensation

CEO salary percentage100.0%
CEO tenure5yrs
CEO ownership0.7%
Management average tenureno data
Board average tenure5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Frank's remuneration changed compared to Revive Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$6m

Jun 30 2024n/an/a

-CA$6m

Mar 31 2024n/an/a

-CA$4m

Dec 31 2023n/an/a

-CA$4m

Sep 30 2023n/an/a

-CA$5m

Jun 30 2023CA$360kCA$360k

-CA$6m

Mar 31 2023n/an/a

-CA$8m

Dec 31 2022n/an/a

-CA$12m

Sep 30 2022n/an/a

-CA$15m

Jun 30 2022CA$360kCA$360k

-CA$18m

Mar 31 2022n/an/a

-CA$24m

Dec 31 2021n/an/a

-CA$22m

Sep 30 2021n/an/a

-CA$20m

Jun 30 2021CA$4mCA$360k

-CA$20m

Mar 31 2021n/an/a

-CA$14m

Dec 31 2020n/an/a

-CA$12m

Sep 30 2020n/an/a

-CA$10m

Jun 30 2020CA$1mCA$220k

-CA$5m

Compensation vs Market: Michael's total compensation ($USD249.71K) is below average for companies of similar size in the German market ($USD468.18K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Frank (63 yo)

5yrs

Tenure

CA$360,000

Compensation

Mr. Michael Frank is Chairman and Chief Executive Officer of Revive Therapeutics Ltd. since December 18, 2019 and its Director. He served as Chairman and CEO at The Good Shroom Co Inc. till April 15, 2021....

Board Members

NamePositionTenureCompensationOwnership
Michael Frank
Chairman & CEO5yrsCA$360.00k0.75%
€ 20.9k
William Jackson
Independent Director10.9yrsno data0.16%
€ 4.3k
Andrew Lindzon
Independent Director5yrsno data0.13%
€ 3.6k
Christian Scovenna
Independent Director5yrsno data0.48%
€ 13.3k
Joshua Herman
Independent Director5yrsno data0.15%
€ 4.2k

5.0yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 31R's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 04:26
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Revive Therapeutics Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Doug CooperBeacon Securities Limited